CPT code 86671 represents an immunoassay laboratory test used to detect antibodies to a specific fungal organism when no more specific CPT code exists. This test is clinically important for diagnosing or supporting the diagnosis of fungal infections that are not covered by targeted assay codes. It affects clinical laboratories, hospital labs, infectious disease clinicians, and payers because it informs diagnostic workups for suspected fungal disease and can influence downstream care decisions.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical role, typical sites of service, and the service type. The publication outlines common billing modifiers associated with laboratory services and identifies areas where payers frequently apply medical necessity and documentation policies. It also summarizes how CPT code 86671 fits into laboratory coding workflows and where this nonspecific fungal antibody assay is used in clinical practice.

This summary does not include state-level policy differences. Data not available in the input: associated taxonomies, specific ICD-10 diagnoses, related billing codes, payer-specific coverage rules, and service-line financial benchmarks.